Clinical trials · Minnesota
Cancer clinical trials in Minnesota
We’re tracking 552 recruiting cancer studies with a site in Minnesota — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Minnesota
- NCT06879041RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This study tests a new radioactive drug, [225Ac]-AZD2284, for men with prostate cancer that has spread and no longer responds to hormone therapy. The drug is designed to target cancer cells and deliver radiation directly to them, potentially slowing the cancer's growth.
Rochester, MinnesotaAges 18 years+ - NCT06510374RecruitingPhase 3
Gene therapy vs. observation for intermediate risk bladder cancer
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
Rochester, MinnesotaAges 18 years+ - NCT07492641RecruitingPhase 3
A new drug plus letrozole for advanced HR+ breast cancer
This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.
Duluth, MinnesotaAges 18 years+ - NCT06764875RecruitingPhase 3
New drug combo for HER2-positive stomach cancer
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
Burnsville, MinnesotaAges 18 years+ - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Burnsville, MinnesotaAges 18 years+ - NCT07805954RecruitingPhase 3
New targeted pills for first-line metastatic pancreatic cancer
This trial tests two new targeted pills (zoldonrasib and daraxonrasib) compared to the standard chemotherapy (gemcitabine and nab-paclitaxel) as the first treatment for metastatic pancreatic cancer with a specific KRAS G12D mutation. The new pills may specifically attack cancer cells with this mutation.
Rochester, MinnesotaAges 18 years+ - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Rochester, MinnesotaAges 18 years+ - NCT06422143RecruitingPhase 3
Keytruda with or without Sac-TMT for advanced squamous lung cancer
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
Minneapolis, MinnesotaAges 18 years+ - NCT05797831RecruitingPhase 2/Phase 3
Maintenance treatment for TP53-wildtype endometrial cancer
This trial tests navtemadlin as a maintenance (ongoing) treatment to help prevent endometrial cancer from coming back after chemotherapy works. It is mainly for people whose cancer has certain genetic features (TP53 “wildtype”) and who had a strong response to first-line taxane–platinum chemo.
Minneapolis, MinnesotaAges 18 years+ - NCT07717437Recruiting
Liver cancer registry for patients who had vein embolization
This registry collects medical images and health information from patients with liver cancer or liver metastases who had a procedure to block certain liver veins (PVE/HVE). The goal is to learn more about this technique and help future patients.
Rochester, MinnesotaAges 18 years+ - NCT07682714Recruiting
Tracking food intake during radiation therapy
This trial asks patients to log their meals using a smartphone app while undergoing radiation therapy for cancer. The goal is to understand how treatment affects eating habits.
Minneapolis, MinnesotaAges 18 years+ - NCT07680790RecruitingPhase 3
New drug combination for advanced egfr lung cancer
This study tests a new drug (izalontamab brengitecan) combined with a standard targeted therapy (osimertinib) compared to standard treatments alone for advanced EGFR-mutant non-small cell lung cancer. It aims to see if the combination works better.
Edina, MinnesotaAges 18 years+ - NCT07659158Recruiting
Virtual resilience program for advanced cancer patients
This trial tests a virtual group program to help people with advanced cancer build resilience and manage stress. It involves online sessions and modules, and aims to improve coping and quality of life.
Rochester, MinnesotaAges 18 years+ - NCT07621718RecruitingPhase 3
Zoldonrasib plus chemotherapy for metastatic pancreatic cancer with KRAS mutation
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
Rochester, MinnesotaAges 18 years+ - NCT07624617Recruiting
Fasting and Breast Cancer Treatment Study
This study looks at whether periods of fasting (eating for shorter time windows) might help improve how well a breast cancer medication called capivasertib works. You'll wear a glucose monitor, track your food, and follow fasting schedules while continuing your regular cancer treatment.
Minneapolis, MinnesotaAges 18 years+ - NCT07560865RecruitingPhase 1
New Cell Therapy for Recurring Brain Cancer
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
Minneapolis, MinnesotaAges 18–75 - NCT07544654RecruitingPhase 3
Study comparing obrixtamig plus chemotherapy for advanced neuroendocrine cancer
This trial tests a new drug called obrixtamig combined with standard chemotherapy for advanced neuroendocrine cancer (a rare type of cancer). You'd receive one cycle of standard chemotherapy first, then be randomly assigned to either continue with the new drug plus chemotherapy or standard chemotherapy alone.
Rochester, MinnesotaAges 18 years+ - NCT07549412RecruitingPhase 3
New chemotherapy drugs for advanced colorectal cancer
This trial tests whether a new chemotherapy combination (precemtabart tocentecan, with or without bevacizumab) works better than a standard treatment for colorectal cancer that has spread and stopped responding to previous drugs. The goal is to find treatments that help people live longer with fewer side effects.
Saint Louis Park, MinnesotaAges 18 years+ - NCT07531095RecruitingPhase 1
Combination drug trial for small cell lung cancer
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
Saint Paul, MinnesotaAges 18–99 - NCT07510334RecruitingPhase 2
VSV Virus Plus Immunotherapy for Advanced Kidney Cancer
This trial tests a combination of a special virus (VSV-IFNβ-NIS) with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced clear cell kidney cancer that hasn't been treated yet. It aims to see if this approach helps shrink tumors or slow the disease.
Rochester, MinnesotaAges 18 years+ - NCT07491445RecruitingPhase 3
Daraxonrasib plus chemo for first-line metastatic pancreatic cancer
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
Rochester, MinnesotaAges 18 years+ - NCT07455058Recruiting
Water Vapor Ablation for Prostate Cancer Long-Term Registry
This registry tracks the long-term effects of Vanquish, a water vapor therapy for prostate cancer. It's for people who are already getting or have gotten this treatment to see how well it works over time.
Woodbury, MinnesotaAges Any age - NCT07419841RecruitingPhase 1
A study of CTX-10726 for certain advanced cancers
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
Rochester, MinnesotaAges 18 years+ - NCT07405801RecruitingPhase 2
Inavolisib plus ribociclib plus fulvestrant for advanced breast cancer
This trial tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) compared to a placebo plus two of the drugs (ribociclib and fulvestrant) for people with advanced hormone receptor-positive breast cancer who have not had prior treatment for advanced disease. The goal is to see if adding inavolisib improves outcomes.
Marshall, MinnesotaAges 18 years+
Cancer trials by city in Minnesota
Where these studies are running in Minnesota
Institutions with a site for the recruiting cancer studies listed above.
- Mayo Clinic · 10 studies
- Research Site · 3 studies
- University of Minnesota · 2 studies
- Allina Health Cancer Institute
- Aspirus St. Luke's Hospital
- Avera Cancer Institute - Marshall
- Elizabeth C. Neil, MD
- Health Partners Cancer Center at Regions Hospital
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in Minnesota?
- Yes. We're currently tracking 552 recruiting cancer studies with a site in Minnesota, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in Minnesota?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Minnesota to take part?
- Not necessarily. These studies have a site in Minnesota, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in Minnesota regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.